Siegel RL, Miller KD, Jemal A. Most cancers Statistics, 2017. CA Most cancers J Clin. 2017;67:7–30.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Well being Group classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
Hehlmann R. How I deal with CML blast disaster. Blood. 2012;120:737–47.
Lim WA, June CH. The Rules of Engineering Immune Cells to Deal with Most cancers. Cell. 2017;168:724–40.
Chen L, Gong W-J, Li M-H, Zhou H-X, Xu M-Z, Qian C-S, et al. Anti-CD19 CAR T-Cell consolidation remedy mixed with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. Blood Adv. 2023;7:4913–25.
Hua J, Qian W, Wu X, Zhou L, Yu L, Chen S, et al. Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Affected person That Relapsed After CART-Cell and Haplo-HSCT Remedy: A Case Report and Assessment of Literature. Onco Targets Ther. 2020;13:2311–7.
Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE, et al. Nilotinib is efficient in imatinib-resistant or -intolerant sufferers with power myeloid leukemia in blastic part. Leukemia. 2012;26:959–62.
Liu F, Sha S, Ma G, Su Y, Xiong Y, He G, et al. Therapy of CML-transformed B Cell Acute Lymphoblastic Leukemia (B-ALL) in Adults with Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Remedy. Stem Cell Rev Rep. 2020;16:1356–8.
Zhou L, Shi H, Shi W, Yang L, Zhang Y, Xu M, et al. Sturdy Molecular Remission in a Lymphoid BP-CML Affected person Harboring T315I Mutation Handled with Anti-CD19 CAR-T Remedy. Onco Targets Ther. 2019;12:10989–95.
Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase area mutation evaluation in power myeloid leukemia sufferers handled with tyrosine kinase inhibitors: suggestions from an professional panel on behalf of European LeukemiaNet. Blood. 2011;118:1208–15.
O’Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase area mutations, drug resistance, and the highway to a remedy for power myeloid leukemia. Blood. 2007;110:2242–9.
Bengió RM, Riva ME, Moiraghi B, Lanari E, Milone J, Ventriglia V, et al. Scientific consequence of power myeloid leukemia imatinib-resistant sufferers: do BCR-ABL kinase area mutations have an effect on affected person survival? First multicenter Argentinean examine. Leuk Lymphoma. 2011;52:1720–6.
Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135:1650–60.
Kamdar M. Embracing chimeric antigen receptors for relapsed power lymphocytic leukaemia. Lancet. 2023;402:590–2.
Jamieson CHM, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl J Med. 2004;351:657–67.
